Study of a novel pancreatic enzyme replacement therapy in pancreatic insufficient subjects with cystic fibrosis

Drucy Borowitz, Christopher H. Goss, Stacey Limauro, Michael W. Konstan, Kathryn Blake, Susan Casey, Alexandra Quittner, Frederick T. Murray

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Objectives: We studied a novel pancreatic enzyme product, ALTU-135, a proprietary formulation of microbially derived lipase, protease, and amylase, to determine its efficacy and safety in treatment of pancreatic insufficiency (PI) in patients with cystic fibrosis (CF). Study design: Ambulatory subjects with CF-PI (n = 117) had baseline coefficient of fat and nitrogen absorption (CFA and CNA, respectively) determined in an inpatient setting while not receiving pancreatic enzyme replacement therapy. Subjects were then randomized to treatment with ALTU-135 containing 5000 (low), 25,000 (mid), or 100,000 (highest) units of lipase (1:1:0.15 of lipase:protease:amylase) for 28 days. After 14 days, CFA and CNA were re-measured. The primary outcomes were change from baseline in CFA and CNA between treatments. Results: Treatment CFA was significantly greater in the mid and highest dose groups compared with that in the low dose group (P = .0229 and P =.0041, respectively); findings were similar for CNA. Subjects with baseline CFA ≤ 40% and >40% in the 2 higher dose groups had a mean increase of 31 and 8 percentage points in CFA, respectively (P < .0001). Conclusion: ALTU-135 was efficacious during the 1-month study period at the dose of 25,000 units of lipase, 25,000 units of protease, and 3750 units of amylase.

Original languageEnglish
JournalJournal of Pediatrics
Volume149
Issue number5
DOIs
StatePublished - Nov 1 2006
Externally publishedYes

Fingerprint

Enzyme Replacement Therapy
Lipase
Cystic Fibrosis
Amylases
Exocrine Pancreatic Insufficiency
Peptide Hydrolases
Therapeutics
Inpatients
Nitrogen
Fats
Safety
Enzymes
ALTU-135

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Study of a novel pancreatic enzyme replacement therapy in pancreatic insufficient subjects with cystic fibrosis. / Borowitz, Drucy; Goss, Christopher H.; Limauro, Stacey; Konstan, Michael W.; Blake, Kathryn; Casey, Susan; Quittner, Alexandra; Murray, Frederick T.

In: Journal of Pediatrics, Vol. 149, No. 5, 01.11.2006.

Research output: Contribution to journalArticle

Borowitz, D, Goss, CH, Limauro, S, Konstan, MW, Blake, K, Casey, S, Quittner, A & Murray, FT 2006, 'Study of a novel pancreatic enzyme replacement therapy in pancreatic insufficient subjects with cystic fibrosis', Journal of Pediatrics, vol. 149, no. 5. https://doi.org/10.1016/j.jpeds.2006.07.030
Borowitz, Drucy ; Goss, Christopher H. ; Limauro, Stacey ; Konstan, Michael W. ; Blake, Kathryn ; Casey, Susan ; Quittner, Alexandra ; Murray, Frederick T. / Study of a novel pancreatic enzyme replacement therapy in pancreatic insufficient subjects with cystic fibrosis. In: Journal of Pediatrics. 2006 ; Vol. 149, No. 5.
@article{469de1eacb0f41e882a324abba9691bc,
title = "Study of a novel pancreatic enzyme replacement therapy in pancreatic insufficient subjects with cystic fibrosis",
abstract = "Objectives: We studied a novel pancreatic enzyme product, ALTU-135, a proprietary formulation of microbially derived lipase, protease, and amylase, to determine its efficacy and safety in treatment of pancreatic insufficiency (PI) in patients with cystic fibrosis (CF). Study design: Ambulatory subjects with CF-PI (n = 117) had baseline coefficient of fat and nitrogen absorption (CFA and CNA, respectively) determined in an inpatient setting while not receiving pancreatic enzyme replacement therapy. Subjects were then randomized to treatment with ALTU-135 containing 5000 (low), 25,000 (mid), or 100,000 (highest) units of lipase (1:1:0.15 of lipase:protease:amylase) for 28 days. After 14 days, CFA and CNA were re-measured. The primary outcomes were change from baseline in CFA and CNA between treatments. Results: Treatment CFA was significantly greater in the mid and highest dose groups compared with that in the low dose group (P = .0229 and P =.0041, respectively); findings were similar for CNA. Subjects with baseline CFA ≤ 40{\%} and >40{\%} in the 2 higher dose groups had a mean increase of 31 and 8 percentage points in CFA, respectively (P < .0001). Conclusion: ALTU-135 was efficacious during the 1-month study period at the dose of 25,000 units of lipase, 25,000 units of protease, and 3750 units of amylase.",
author = "Drucy Borowitz and Goss, {Christopher H.} and Stacey Limauro and Konstan, {Michael W.} and Kathryn Blake and Susan Casey and Alexandra Quittner and Murray, {Frederick T.}",
year = "2006",
month = "11",
day = "1",
doi = "10.1016/j.jpeds.2006.07.030",
language = "English",
volume = "149",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Study of a novel pancreatic enzyme replacement therapy in pancreatic insufficient subjects with cystic fibrosis

AU - Borowitz, Drucy

AU - Goss, Christopher H.

AU - Limauro, Stacey

AU - Konstan, Michael W.

AU - Blake, Kathryn

AU - Casey, Susan

AU - Quittner, Alexandra

AU - Murray, Frederick T.

PY - 2006/11/1

Y1 - 2006/11/1

N2 - Objectives: We studied a novel pancreatic enzyme product, ALTU-135, a proprietary formulation of microbially derived lipase, protease, and amylase, to determine its efficacy and safety in treatment of pancreatic insufficiency (PI) in patients with cystic fibrosis (CF). Study design: Ambulatory subjects with CF-PI (n = 117) had baseline coefficient of fat and nitrogen absorption (CFA and CNA, respectively) determined in an inpatient setting while not receiving pancreatic enzyme replacement therapy. Subjects were then randomized to treatment with ALTU-135 containing 5000 (low), 25,000 (mid), or 100,000 (highest) units of lipase (1:1:0.15 of lipase:protease:amylase) for 28 days. After 14 days, CFA and CNA were re-measured. The primary outcomes were change from baseline in CFA and CNA between treatments. Results: Treatment CFA was significantly greater in the mid and highest dose groups compared with that in the low dose group (P = .0229 and P =.0041, respectively); findings were similar for CNA. Subjects with baseline CFA ≤ 40% and >40% in the 2 higher dose groups had a mean increase of 31 and 8 percentage points in CFA, respectively (P < .0001). Conclusion: ALTU-135 was efficacious during the 1-month study period at the dose of 25,000 units of lipase, 25,000 units of protease, and 3750 units of amylase.

AB - Objectives: We studied a novel pancreatic enzyme product, ALTU-135, a proprietary formulation of microbially derived lipase, protease, and amylase, to determine its efficacy and safety in treatment of pancreatic insufficiency (PI) in patients with cystic fibrosis (CF). Study design: Ambulatory subjects with CF-PI (n = 117) had baseline coefficient of fat and nitrogen absorption (CFA and CNA, respectively) determined in an inpatient setting while not receiving pancreatic enzyme replacement therapy. Subjects were then randomized to treatment with ALTU-135 containing 5000 (low), 25,000 (mid), or 100,000 (highest) units of lipase (1:1:0.15 of lipase:protease:amylase) for 28 days. After 14 days, CFA and CNA were re-measured. The primary outcomes were change from baseline in CFA and CNA between treatments. Results: Treatment CFA was significantly greater in the mid and highest dose groups compared with that in the low dose group (P = .0229 and P =.0041, respectively); findings were similar for CNA. Subjects with baseline CFA ≤ 40% and >40% in the 2 higher dose groups had a mean increase of 31 and 8 percentage points in CFA, respectively (P < .0001). Conclusion: ALTU-135 was efficacious during the 1-month study period at the dose of 25,000 units of lipase, 25,000 units of protease, and 3750 units of amylase.

UR - http://www.scopus.com/inward/record.url?scp=33751119814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751119814&partnerID=8YFLogxK

U2 - 10.1016/j.jpeds.2006.07.030

DO - 10.1016/j.jpeds.2006.07.030

M3 - Article

VL - 149

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 5

ER -